ChainCatcher news, Nasdaq-listed biotechnology company Windtree Therapeutics (WINT) announced that it has signed a common stock purchase agreement of up to $500 million to establish an equity line of credit (ELOC). In addition, the company has also signed an additional stock purchase agreement worth $20 million with Build and Build Corp.
The total financing scale reaches up to 520 million dollars, of which 99% of the funds will be used to purchase BNB. The company plans to officially start using the funds after obtaining shareholder approval to increase the authorized number of common stocks.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Windtree signs a new financing protocol of 520 million USD to strengthen its BNB reserve strategy.
ChainCatcher news, Nasdaq-listed biotechnology company Windtree Therapeutics (WINT) announced that it has signed a common stock purchase agreement of up to $500 million to establish an equity line of credit (ELOC). In addition, the company has also signed an additional stock purchase agreement worth $20 million with Build and Build Corp. The total financing scale reaches up to 520 million dollars, of which 99% of the funds will be used to purchase BNB. The company plans to officially start using the funds after obtaining shareholder approval to increase the authorized number of common stocks.